TY - JOUR
T1 - VEGF gene delivery for treatment of ischemic cardiovascular disease
AU - Koransky, Mark L.
AU - Robbins, Robert C.
AU - Blau, Helen M.
PY - 2002
Y1 - 2002
N2 - There are increasing numbers of patients with ischemic myocardial disease not amenable to traditional methods of revascularization. These patients may benefit from new research into the use of naturally occurring angiogenic compounds, such as vascular endothelial growth factor (VEGF) for re-establishing blood flow into regions of hibernating myocardium. Animal studies and human clinical trials evaluating VEGF demonstrate increases in myocardial perfusion after treatment, with some patients reporting improvement in anginal symptoms. Further research into the ideal form of VEGF therapy (protein, plasmid, or adenoviral) and delivery method (intracoronary, intramyocardial, or epicardial) seems justified.
AB - There are increasing numbers of patients with ischemic myocardial disease not amenable to traditional methods of revascularization. These patients may benefit from new research into the use of naturally occurring angiogenic compounds, such as vascular endothelial growth factor (VEGF) for re-establishing blood flow into regions of hibernating myocardium. Animal studies and human clinical trials evaluating VEGF demonstrate increases in myocardial perfusion after treatment, with some patients reporting improvement in anginal symptoms. Further research into the ideal form of VEGF therapy (protein, plasmid, or adenoviral) and delivery method (intracoronary, intramyocardial, or epicardial) seems justified.
UR - http://www.scopus.com/inward/record.url?scp=0036237972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036237972&partnerID=8YFLogxK
U2 - 10.1016/S1050-1738(01)00158-X
DO - 10.1016/S1050-1738(01)00158-X
M3 - Review article
C2 - 12007735
AN - SCOPUS:0036237972
SN - 1050-1738
VL - 12
SP - 108
EP - 114
JO - Trends in Cardiovascular Medicine
JF - Trends in Cardiovascular Medicine
IS - 3
ER -